Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Next Previous
Search
Trial Profile

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalbavancin (Primary) ; Linezolid; Vancomycin
  • Indications Gram-positive infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Acronyms DISCOVER-1
  • Sponsors Durata Therapeutics

Most Recent Events

  • 25 Apr 2017 Results of pooled analysis of clearance of bacteraemia data fro four phase III stuadies and a phase II study including this study presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
  • 30 Oct 2016 Pooled results of this and other 3 trial (VER001-9, DUR001-302 and DUR001-303) presented at the IDWeek 2016
  • 02 Mar 2015 According to an Actavis media release, the EC has granted Actavis' subsidiary Durata Therapeutics International B.V. marketing authorization for XYDALBA for the treatment of acute bacterial skin and skin structure infections in adults.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top